<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Endocrine adverse events in patients treated with immune checkpoint inhibitors: a comprehensive analysis

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

Organization Authors

Co-Authors

Dokmetas, Meric

Muglu, Harun

Ozcan, Erkan

Helvaci, Kaan

Kalaci, Ender

Kahraman, Seda

Aykan, Musa Baris

Cicin, Irfan

Olmez, Omer Fatih

Bilici, Ahmet

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background and Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but their use is associated with a spectrum of immune-related adverse events (irAEs), including endocrine disorders. This study aims to investigate the incidence, timing, treatment modalities, and impact of ICI-related endocrine side effects in cancer patients. Materials and Methods: This retrospective study analyzed 139 cancer patients treated with ICIs between 2016 and 2022. Data regarding endocrine irAEs, including hypothyroidism, hyperthyroidism, hypophysitis, and diabetes mellitus, were collected. The study examined the timing of irAE onset, management approaches, and the association between irAEs and treatment outcomes. Results: The most common endocrine irAE was hypothyroidism (65.5%), followed by hyperthyroidism (2.3%), hypophysitis (8.6%), and diabetes mellitus (0.7%). These disorders typically emerged within the first six months of ICI therapy. Most cases were managed conservatively or with hormone replacement therapy. Patients who developed endocrine irAEs exhibited a higher objective response rate (ORR) and clinical benefit rate (CBR) compared to those without irAEs. Conclusions: Endocrine dysfunction is a significant toxicity of ICI therapy. Early recognition, prompt diagnosis, and appropriate management are crucial to minimize their impact on patient health and quality of life. This study highlights the potential association between irAEs and improved clinical outcomes. Further research is needed to elucidate the underlying mechanisms and identify predictive biomarkers for irAE development.

Source

Publisher

Multidisciplinary Digital Publishing Institute (MDPI)

Citation

item.page.haspartof

Source

Medicina

item.page.ispartofseries

item.page.edition

DOI

10.3390/medicina61010123

item.page.datauri

item.page.link

Rights

CC BY (Attribution)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY (Attribution)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators